What is the 13F Pro Quality Score for MDLN?

13F Pro ranks Medline Inc. (MDLN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDLN's current score at https://13fpro.ai/company/MDLN (free sign-up required for the full ranking).

Which hedge funds own the most MDLN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDLN include Carlyle Group, H&F Corporate Investors X, Ltd., FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MDLN as soon as new 13F filings post.

Where does 13F Pro source MDLN data?

All Medline Inc. fundamentals and ownership data come directly from SEC EDGAR. Medline Inc. files with the SEC under CIK 2046386. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDLN in?

Medline Inc. (MDLN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives MDLN's revenue?

Per Medline Inc.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Supply Chain Solutions ($4,145M, +16.3% YoY); Medline Brand ($3,540M, +6.6% YoY); Front Line Care ($1,652M, +3.8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MDLN.

What are MDLN's largest expenses?

Medline Inc.'s latest 10-Q reports these as the largest expense items: Cost of goods sold ($5,470M, +9.8% YoY); Selling, general and administrative expenses ($1,295M, +20.7% YoY); Other operating expenses ($348M, +334M YoY (NM)). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 27, 2026).

How often is MDLN research updated on 13F Pro?

MDLN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Medline Inc.(MDLN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 2046386 MDLN stock profile & AI dashboard →

13F Pro Quality Score

62.5/100

Rank #704 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

58.8/100

Profitability

41.6/100

Balance Sheet

51.1/100

Earnings Quality

89.1/100

Free Cash Flow

44.1/100

Institutional Flow

97.8/100

Revenue Scale

94.8/100

Dilution Risk

83.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MDLN Scores 63/100

exact factor attribution · 2026-09-11

MDLN's composite is driven by scale and earnings quality, held back by earnings growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.7 pts

95th pct

Earnings quality

+3.9 pts

89th pct

Institutional flow

+2.4 pts

98th pct

Revenue growth

+1.8 pts

59th pct

Shareholder dilution

+1.7 pts

84th pct

Capital efficiency

+0.1 pts

51th pct

Free cash flow

-0.9 pts

44th pct

Profitability

-1.3 pts

42th pct

Earnings growth

-2.0 pts

11th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MDLN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Medline Inc. (MDLN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDLN at 62.5/100 on a 32-signal composite quality model, placing it at rank #704 of 2,961 stocks — the top 25% of the AI-ranked universe. MDLN scores in the top quartile across institutional flow (97.8), revenue scale (94.8), earnings quality (89.1). Based on the latest XBRL financial filings (Q2 2026), Medline Inc. reports quarterly revenue of $7.7B, net income of $139.0M, an operating margin of 5.1%. Top institutional holders of MDLN by reported 13-F value include Carlyle Group, H&F Corporate Investors X, Ltd., FMR, based on the most recent SEC filings. MDLN trades on the Nasdaq exchange and files with the SEC under CIK 2046386. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medline Inc. directly from SEC EDGAR. Medline Inc.'s 13F Pro composite quality score has ranged between 47 and 65 since 2026, currently 62.5 — a stable long-term trajectory across 19 quarterly and live scoring snapshots.

What's Driving MDLN's Business? Latest 10-Q Breakdown

✓ 31/31 datapoints verified

AI-extracted from Medline Inc.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales grew 11.6% YoY to $7.7B, but net income fell 58.3% YoY to $139M as a $336M fire at the Tracy, California distribution center and a post-IPO effective tax rate jump to 40.9% offset revenue growth.

Biggest Revenue Drivers

Supply Chain Solutions$4,145M+16.3% YoY

Driven by volume growth in Prime Vendor sales, including new relationship signings and growth with existing customers

Medline Brand$3,540M+6.6% YoY

Driven by volume growth in Prime Vendor sales, partially offset by $89M of customer repayments associated with tariff refunds

Biggest Revenue Drivers

Total revenue: $7.7B+11.6% YoY

Supply Chain Solutions$4,145M+16.3% YoY

Driven by volume growth in Prime Vendor sales, including new relationship signings and growth with existing customers

Medline Brand$3,540M+6.6% YoY

Driven by volume growth in Prime Vendor sales, partially offset by $89M of customer repayments associated with tariff refunds

Within Medline Brand

Front Line Care$1,652M+3.8% YoY

Volume growth including exam gloves and personal care products, partially offset by tariff refund customer repayments

Surgical Solutions$1,640M+8.7% YoY

Volume growth in kitting and operating room products, partially offset by tariff refund customer repayments

Laboratory and Diagnostics$248M+12.2% YoY

Volume growth in laboratory products

Largest Expense Items

Cost of goods sold$5,470M+9.8% YoY

Growth in net sales and higher import costs due to tariffs, partially offset by tariff refunds

Selling, general and administrative expenses$1,295M+20.7% YoY

$156M higher compensation and benefits from headcount investment (incl. $15M one-time IPO bonuses) and $24M higher distribution/outbound freight expense

Other operating expenses$348M+334M YoY (NM)

Primarily driven by the fire at the Tracy, California distribution center

Margins: Gross margin expanded to 28.8% from 27.7% on net tariff refunds, partially offset by higher import costs from tariffs. Operating income still fell 38.5% YoY to $395M as the Tracy fire loss and higher SG&A outweighed gross profit gains.

Watch Items from the Filing

A June 11, 2026 fire destroyed the Tracy, California distribution center, causing $336M of estimated losses ($204M inventory, $116M fixed assets, $16M other) with no insurance recoveries yet recorded.
Effective income tax rate jumped to 40.92% from 7.16% YoY, driven by the post-IPO Reorganization subjecting more income to corporate-level U.S. federal and state taxes.
Three unresolved FDA warning letters cover Quality Management System and cGMP compliance at the Northfield, Glens Falls, and Waukegan facilities, with remediation expected to raise costs in H2 FY2026.
Tariffs had a ~$110M net negative impact on pretax income in Q2, while the company expects ~$507M in total IEEPA tariff refund claims following a Supreme Court ruling invalidating the tariffs.
Supply Chain Solutions Segment Adjusted EBITDA margin fell to 4.9% from 5.6% YoY due to customer mix from new Prime Vendor signings at lower margins.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$7.7B

Net Income

Q2 2026

$139.0M

Free Cash Flow

Q2 2026

$604.0M

Operating Margin

Q2 2026

5.1%

ROIC

Q2 2026

6.5%

D/E Ratio

Q2 2026

1.09

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.5% YoY

$28.43BFY 2025

FY23 $23.23BFY24 $25.51BFY25 $28.43B

Net Income

$1.16BFY 2025

FY23 —FY24 —FY25 $1.16B

Operating Income

+3.1% YoY

$2.21BFY 2025

FY23 $1.25BFY24 $2.15BFY25 $2.21B

EPS (Diluted)

$-0.01FY 2025

FY23 —FY24 —FY25 $-0.01

Total Assets

+7.0% YoY

$38.48BFY 2025

FY23 —FY24 $35.98BFY25 $38.48B

Total Debt

-23.7% YoY

$12.64BFY 2025

FY23 —FY24 $16.57BFY25 $12.64B

Op. Cash Flow

-1.4% YoY

$1.74BFY 2025

FY23 $1.69BFY24 $1.77BFY25 $1.74B

Free Cash Flow

-8.3% YoY

$1.30BFY 2025

FY23 $1.41BFY24 $1.42BFY25 $1.30B

Metric	FY 2025	FY 2024	FY 2023
Revenue	$28.43B +11.5%	$25.51B +9.8%	$23.23B
Net Income	$1.16B	—	—
Operating Income	$2.21B +3.1%	$2.15B +71.7%	$1.25B
EPS (Diluted)	$-0.01	—	—
Total Assets	$38.48B +7.0%	$35.98B	—
Total Debt	$12.64B -23.7%	$16.57B	—
Operating Cash Flow	$1.74B -1.4%	$1.77B +5.0%	$1.69B
Free Cash Flow	$1.30B -8.3%	$1.42B +0.4%	$1.41B

Get alerted when MDLN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medline Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDLN

Carlyle Group Inc.
$7.4B187,083,713 sh
H&F Corporate Investors X, Ltd.
$2.8B70,874,326 sh
FMR LLC
$1.9B46,963,203 sh
Capital Research Global Investors
$1.6B39,963,790 sh
Invesco Ltd.
$1.5B38,346,937 sh
BlackRock, Inc.
$1.0B26,393,587 sh
MORGAN STANLEY
$852.1M21,605,662 sh
LONE PINE CAPITAL LLC
$827.0M20,968,367 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$787.1M19,888,806 sh
VANGUARD CAPITAL MANAGEMENT LLC
$702.7M17,816,057 sh

Fund	Value	Shares
Carlyle Group Inc.	$7.4B	187,083,713
H&F Corporate Investors X, Ltd.	$2.8B	70,874,326
FMR LLC	$1.9B	46,963,203
Capital Research Global Investors	$1.6B	39,963,790
Invesco Ltd.	$1.5B	38,346,937
BlackRock, Inc.	$1.0B	26,393,587
MORGAN STANLEY	$852.1M	21,605,662
LONE PINE CAPITAL LLC	$827.0M	20,968,367
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$787.1M	19,888,806
VANGUARD CAPITAL MANAGEMENT LLC	$702.7M	17,816,057

Companies Similar to MDLN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

HUM

HUMANA INC

AI score

Similar quality profile · 23 shared holders

Capital Research Global Investors National Pension Service Capital World Investors

ELV

Elevance Health, Inc.

AI score

Similar quality profile · 13 shared holders

BAILLIE GIFFORD & CO Artisan Partners Limited Partnership Alyeska Investment Group, L.P.

CVS

CVS HEALTH Corp

AI score

Similar quality profile · 22 shared holders

Capital Research Global Investors VIKING GLOBAL INVESTORS LP Alyeska Investment Group, L.P.

UNH

UNITEDHEALTH GROUP INC

AI score

Similar quality profile · 19 shared holders

Capital Research Global Investors T. Rowe Price Investment Management, Inc.Unisphere Establishment

BDX

BECTON DICKINSON & CO

AI score

Similar quality profile · 15 shared holders

T. Rowe Price Investment Management, Inc.National Pension Service Mawer Investment Management Ltd.

CNC

CENTENE CORP

AI score

Similar quality profile · 20 shared holders

Robeco Institutional Asset Management B.V.WORLDQUANT MILLENNIUM ADVISORS LLC National Pension Service

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Similar quality profile · 15 shared holders

Alberta Investment Management Corp National Pension Service Tredje AP-fonden

IQV

IQVIA HOLDINGS INC.

AI score

Similar quality profile · 14 shared holders

Artisan Partners Limited Partnership National Pension Service Robeco Institutional Asset Management B.V.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDLN on your watchlist

Track score changes the day Medline Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDLN a good stock to buy?

13F Pro's AI-powered analysis of Medline Inc. (MDLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDLN are available on the MDLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDLN is classified as a large company.

Which hedge funds own MDLN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medline Inc.'s investment landscape.